ArticleBiomedicines2021
Streptozotocin-Induced Diabetes in a Mouse Model (BALB/c) Is Not an Effective Model for Research on Transplantation Procedures in the Treatment of Type 1 Diabetes.
Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Effects ofFrontiers in pharmacology · 2022Pooled it
- Dose-Dependent Protective Effects of Agmatine on Sublingual Gland Dysfunction and Pancreatic Damage in Experimental Diabetes: Evidence From Histological, Biochemical, and Immunohistochemical Analyses.Microscopy research and technique · 2026Article
- Alpha‑lipoic acid-loaded chitosan nanoparticles ameliorate streptozotocin‑induced diabetic liver injury via Nrf2/HO‑1 activation and TLR4/NF‑κB and JAK2/STAT1 inhibition.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Investigation of the Efficacy of Orientin in Streptozotocin-Induced Type 1 Diabetes Model and Pancreatic Beta-TC6 Cells.Journal of biochemical and molecular toxicology · 2026Article
- Differential Anti-Inflammatory Effects of Semaglutide and Tirzepatide in Experimental Diabetes Mellitus.Current issues in molecular biology · 2026Article
- Article
- Purification and Characterization of Gamma-Aminobutyric Acid (GABA) from E. faecium BS5 and Its Antidiabetic Efficacy in Streptozotocin-Induced Diabetic Rats.Probiotics and antimicrobial proteins · 2026Article
- Calcium Nanoliposome Improves Glycemic Control in a Mouse Diabetes Mellitus Model.Pharmaceutical nanotechnology · 2026Article
- Targeted animal models for preclinical assessment of cellular and gene therapies in pancreatic and liver diseases: regulatory and practical insights.Cytotherapy · 2025Review
- Exacerbation of diabetes due to F. Nucleatum LPS-induced SGLT2 overexpression in the renal proximal tubular epithelial cells.BMC nephrology · 2025Article
- The Abnormal Expression of Tubular SGLT2 and GULT2 in Diabetes Model Mice with Malocclusion-Induced Hyperglycemia.Biomedicines · 2025Article
- Dose-dependent progression of multiple low-dose streptozotocin-induced diabetes in mice.Physiological genomics · 2023Article
- Bioprinted 3D Bionic Scaffolds with Pancreatic Islets as a New Therapy for Type 1 Diabetes-Analysis of the Results of Preclinical Studies on a Mouse Model.Journal of functional biomaterials · 2023Article
- Dose-dependent progression of multiple low dose streptozotocin-induced diabetes in mice.bioRxiv : the preprint server for biology · 2023Article
- Rodent models for diabetes.3 Biotech · 2023Review
- A Review of Medicinal Plants with Renoprotective Activity in Diabetic Nephropathy Animal Models.Life (Basel, Switzerland) · 2023Review
- Molecular and morphological alterations in uninjured skin of streptozotocin-induced diabetic mice.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Type 1 diabetes (T1D) is characterized by the destruction of over 90% of the β-cells. C-peptide is a parameter for evaluating T1D. Streptozotocin (STZ) is a standard method of inducing diabetes in animals. Eight protocols describe the administration of STZ in mice; C-peptide levels are not taken into account. The aim of the study is to determine whether the STZ protocol for the induction of beta-cell mass destruction allows for the development of a stable in vivo mouse model for research into new transplant procedures in the treatment of type 1 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.